Biocept Liquid Biopsy MET Amplification Test

May 04, 2015

Biocept announced it has launched a blood-based c-MET amplification test to help physicians identify which patients may be receptive or resistant to certain gastric and non-small cell lung cancer treatments. 

More Like This

May 25, 2018

Phase Genomics, Pacific Biosciences FALCON-Phase

Phase Genomics and Pacific Biosciences have launched  genome assembly software that combines PacBio single-molecule sequencing data with Hi-C scaffolding technology to assemble phased genomes. The FALCON-Phase software is available open source and as a service through Phase Genomics.

May 25, 2018

Asuragen AmplideX PCR/CE DMPK Kit

Asuragen has launched the AmplideX PCR/CE DMPK Kit, a research-use-only assay designed to simplify analysis of repeat expansions in the DMPK gene, which is implicated in myotonic dystrophy type 1 (Steinert's disease). The repeat expansions in DMPK commonly extend beyond 1,000 CTG repeats and therefore have previously required the use of Southern blot technology to estimate their size, Asuragen noted, adding that its new kit is a signficant improvement over this process.

May 22, 2018

SomaGenics RealSeq-Biofluids

SomaGenics has launched RealSeq-biofluids, a next-generation sequencing library construction kit sensitive for detecting small RNAs in cell-free biofluids. Based on the company's bias-free RealSeq technology, the new kit is designed to allow researchers to sequence small RNAs from as little as 50 µl of plasma or other body fluids.

May 17, 2018

Precipio KRAS Liquid Biopsy Kits for Pancreatic Cancer

Precipio has launched two new research-use only ICEme kits for the detection of mutations in KRAS Exons 2 and 3 in pancreatic cancer. The kits use the company's proprietary ICE-COLD PCR liquid biopsy technology and are available for both qPCR and Sanger sequencing platforms. According to Precipio, its non-invasive, low-cost enrichment technology is well-suited for laboratories developing screening and monitoring tests. The kits will be priced at approximately $100 per specimen.

May 17, 2018

Bluebee Bluebase Assay

Bluebee has announced the release of its Bluebase assay, which is designed to run on the Bluebee core data analysis platform and provides post-sequencing intelligent data aggregation, ease of querying, and deep knowledge mining. The technology aggregates, organizes, and stores combined genomic data sets, phenotypes, and other metadata from a group of public and private databases. Bluebase allows for a range of applications, including discovery and validation of biomarkers, insight into patient stratification approaches, cross-study analyses by multidisciplinary teams, and identification of drug candidates for clinical trials. BlueBee noted that Bluebase is targeted toward diagnostic assay developers, pharmaceutical researchers, clinical trial operators, and investigators of population-scale initiatives. 

May 16, 2018

DDN Storage/Parabricks Genomic Analysis Platform

DDN Storage and Parabricks announced the availability of a jointly integrated technology platform that massively accelerates human genome analysis. The platform DDN's high-performance Parallel Flash Data Platforms and Parabricks' DNA Bricks application to deliver a "unified genomics analysis infrastructure that provides performance, simplicity, and flexibility for end users, the companies said. The new GPU and storage solution can analyze 1,500 genomes a week, accelerating precision medicine workflows by 100x, the companies said. For example, they noted that the platform can take an industry-standard pipeline, like GATK4, and shrink run time from more than 30 hours down to mere minutes.

May 16, 2018

Veracyte Afirma Xpression Atlas

Veracyte has launched its Afirma Xpression Atlas test for thyroid cancer. The test uses RNA sequencing to analyze 761 DNA variants and 130 RNA fusions in over 500 genes that have been linked to thyroid cancer. The test's aim is to provide information to help clinicians make surgery and treatment decisions for patients who have thyroid nodules.

May 15, 2018

Invivoscribe LymphoTrack Dx TRB Assay

InvivoScribe Technologies has released its LymphoTrack Dx TRB Assay for the Illumina MiSeq platform, a CE-marked next-generation sequencing kit for in vitro diagnostic use. The assay completes the menu of Invivoscribe's CE-marked clonality assays on the MiSeq, enabling small and large laboratories to identify and track clonal rearrangements.

May 14, 2018

Interpace Diagnostics ThyGeNext

Interpace Diagnostics said it is launching ThyGenNext, a mutational panel for indeterminate thyorid nodules, at the American Association of Clinical Endocrinologists annual meeting this week. ThyGeNext builds on the company's ThyGenX panel (launched in August 2014) by adding numerous molecular markers, gene mutations, and RNA fusions, resulting in a more comprehensive set of indicators to identify malignant or benign nodules and ascertain aggressiveness and other characteristics. Specifically, it uses next-generation sequencing to identify more than 150 genetic alterations assciated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer.

May 11, 2018

Oxford Nanopore MinKnow Software

Oxford Nanopore Technologies has released an updated version of its MinKnow software, which controls its MinIon, GridIon, and PromethIon sequencing platforms. Among other changes, the new version includes a feature called "progressive unblock," which helps increase the data yield of a flow cell, and active voltage control, which improves signal consistency during a run.

May 09, 2018

Karius NGS Pathogen Test

Karius has launched a quantitative version of its next-generation sequencing-based test that identifies microbial cell-free DNA in blood. According to the company, the test can identify DNA from more than 1,000 pathogens including bacteria, DNA viruses, fungi, mold, and protozoa.

May 08, 2018

Intermountain Healthcare RxMatch Comprehensive Panel

Intermountain Precision Genomics Core Laboratory said its RxMatch Comprehensive Panel has expanded to 97 gene targets from 36. Originally launched last September as an anti-depressent panel, it now includes opioids, statins, immunosuppresants, anti-depressants, and others. Patients provide a DNA sample with a cheek swab collected in a physician's office. Results are available within about a week. Intermountain Precision Genomics Core Laboratory is part of Intermountain Healthcare.

May 04, 2018

Bio-Rad Bio-Plex Pro Human Cytokine Screening Panel

Bio-Rad Laboratories has launched the Bio-Plex Pro Human Cytokine Screening Panel, a multiplex assay that can identify and quantify 48 different analytes linked to heart disease, autoimmunity and allergy, cancer, and other conditions.

The panel detects targets related to adaptive immunity cytokines, pro-inflammatory cytokines, and anti-inflammatory cytokines, all in a single well. It is available in a 96-well kit format that includes premixed magnetic capture beads and detection antibodies, multiplexed standards and controls, secondary antibodies for fluorescence detection, and buffers. The panel is compatible with the Bio-Plex MAGPIX Multiplex Reader, Bio-Plex 200 and Bio-Plex 3D Multiplex Immunoassay Systems, LX200 Instrument, and Flexmap 3D System, and data can be managed and analyzed using Bio-Plex Manager and Bio-Plex Data Pro Software.

May 02, 2018

PredicineATLAS

Predicine has launched a new liquid biopsy panel called PredicineATLAS, which covers 600 genes and offers a readout of patients tumor mutational burden to help inform and assess immuno-oncology treatment.

The assay will be available first for research use only though an early access program, but the company aims to at some point add a CLIA-certified version as well.

Apr 26, 2018

Agilent In Situ Hybridization Probes

Agilent Technologies introduced a number of in situ hybridization probes, including the EBER RNA CISH, Kappa, and Lambda mRNA CISH probes for Dako Omnis. Additionally, a manual IQFISH panel for lymphoma was launched following its CE marking. 

The EBER RNA CISH, Kappa, and Lambda mRNA CISH releases increase the diagnostic capabilities of the Dako Omnis instrument, which can now be used to simultaneously run tests involving CISH, FISH, and immunohistochemistry. Meanwhile, the IQFISH panel is a set of oligonucleotide-based FISH probes for detecting rearrangements involving the MYC, CBL2, BCL6, MALT1, CCND1, and IGH genes. The probes are for use on formalin-fixed, paraffin-embedded tissue sections, Agilent said, adding they are available in break-apart and dual-fusion methodologies.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.